SCHEMBL2261966

SCHEMBL2261966

Cc1cc(C#N)cc(C)c1Oc1nc(NC2CCN(c3cccc(CC(N)=O)c3)CC2)ncc1Br

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 8/20 0.52
CYP2C9 P11712 6/20 0.47
JAK2 O60674 3/20 0.37
JAK3 P52333 3/20 0.37
JAK1 P23458 2/20 0.37
CHRM4 P08173 1/20 0.37
CYP2C19 P33261 5/20 0.36
RPS6KB1 P23443 1/20 0.36
CYP3A4 P08684 4/20 0.36
CYP2D6 P10635 4/20 0.36
ADORA1 P30542 2/20 0.36
ABCC3 O15438 1/20 0.36
ESR1 P03372 1/20 0.36
CYP1A2 P05177 1/20 0.36
PGR P06401 1/20 0.36
CHRM2 P08172 1/20 0.36
ABCB1 P08183 1/20 0.36
ADRA2A P08913 1/20 0.36
CHRM1 P11229 1/20 0.36
DRD1 P21728 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2264021 0.90 KCNH2 (0.50) KCNH2CYP2C9JAK2JAK3JAK1
SCHEMBL16966438 0.90 KCNH2 (0.47) KCNH2CYP2C9JAK2JAK3JAK1
SCHEMBL2263186 0.90 KCNH2 (0.56) KCNH2CYP2C9JAK2JAK3JAK1
SCHEMBL2264469 0.90 KCNH2 (0.47) KCNH2CYP2C9JAK2CHRM4CYP2C19
SCHEMBL16966436 0.89 KCNH2 (0.47) KCNH2CYP2C9JAK2JAK3JAK1
SCHEMBL2259839 0.89 KCNH2 (0.47) KCNH2CYP2C9CHRM4ADORA1PTK2
SCHEMBL2263559 0.89 KCNH2 (0.51) KCNH2CYP2C9JAK2JAK3JAK1
SCHEMBL2260520 0.88 KCNH2 (0.47) KCNH2CYP2C9CHRM4CYP2C19CYP3A4
SCHEMBL2263215 0.88 KCNH2 (0.45) KCNH2CYP2C9CHRM4CYP2C19CYP3A4
SCHEMBL2262338 0.87 KCNH2 (0.47) KCNH2CYP2C9CHRM4CYP2C19CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2089384-B1 2-(PIPERIDIN-4-YL)-4-PHENOXY-OR PHENYLAMINO-PYRIMIDINE DERIVATIVES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS HOFFMANN LA ROCHE (CH) 2015-08-05 EP claimed
US-7998969-B2 enzyme inhibitors such as 4-[2-(1-Benzyl-piperidin-4-ylamino)-pyrimidin-4-yloxy]-3,5-dimethyl-benzonitrile, used in combination with other viricides, for preventing and treatment of viral infections such as HIV, AIDS and AIDS related diseases ROCHE PALO ALTO LLC (US) 2011-08-16 US claimed
EP-2089384-A2 2-(PIPERIDIN-4-YL)-4-PHENOXY-OR PHENYLAMINO-PYRIMIDINE DERIVATIVES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS F. Hoffmann-Roche AG (CH) 2009-08-19 EP claimed
US-20080146595-A1 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC 2008-06-19 US claimed
WO-2008071587-A2 2-(PIPERIDIN-4-YL)-4-PHENOXY- OR PHENYLAMINO-PYRIMIDINE DERIVATIVES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2008-06-19 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146595-A1 Non-nucleoside reverse transcriptase inhibitors NQO2, SAMHD1, POLR2A KCNH2 4033/4885CYP2C9 1382/4885JAK2 3419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.